Inavir is the lead product in a range of second-generation antivirals co-owned by Biota Scientific Management Pty, Ltd and Daiichi Sankyo.

Government Funds Development of Single Dose Flu Antiviral

The U.S. Biomedical Advanced Research and Development Authority, BARDA, announced the $231 million, five-year contract on March 31.

A $231 million contract for five years will fund the activities needed to bring a new influenza antiviral drug to the point of FDA approval for use in the United States, the U.S. Biomedical Advanced Research and Development Authority, BARDA, announced March 31. The five-year contract with Biota Scientific Management Pty, Ltd of Melbourne, Australia, is intended to develop a drug named CS-8958, which is currently sold in Japan under the name Inavir®. A single dose is the full treatment.

Current FDA-approved antivirals oseltamivir (Tamiflu®) and zanamivir (Relenza®) require five days of twice daily dosing, according to HHS. BARDA is an agency within the Office of the Assistant Secretary for Preparedness and Response in HHS.

With the Japanese firm Daiichi Sankyo, Biota co-owns a range of second-generation influenza antivirals, of which Inavir is the lead product; Inavir is Daiichi Sankyo's registered brand for laninamivir octanoate, according to Biota.

"This award represents another critical step forward in ensuring that safe and effective antiviral drugs are available for the treatment of influenza," said BARDA Director Dr. Robin Robinson. "The ability to treat influenza by delivering a single dose of medicine would provide real advantages to doctors and patients during an emergency and would be an important addition to our pandemic influenza arsenal."

Inavir is not a vaccine. It is a long-acting neuraminidase inhibitor that prevents flu virus from spreading in the body's cells. The drug is delivered via a dry powder inhaler.

Under the contract, Biota Scientific will set up U.S. manufacturing of the drug, optimize its manufacturing processes, and conduct clinical trials for safety and efficacy in adult and pediatric populations. The contract is part of BARDA's implementation of the national pandemic influenza preparedness strategy, which includes accelerated development of new antivirals.

Download Center

HTML - No Current Item Deck
  • Safety Management Software - Free Demo

    IndustrySafe Safety Software’s comprehensive suite of modules help organizations to record and manage incidents, inspections, hazards, behavior based safety observations, and much more. Improve safety with an easy to use tool for tracking, notifying and reporting on key safety data.

  • Create Flexible Safety Dashboards

    IndustrySafe’s Dashboard Module allows organizations allows you to easily create and view safety KPIs to help you make informed business decisions. Our best of breed default indicators can also save you valuable time and effort in monitoring safety metrics.

  • Schedule and Record Observations

    IndustrySafe's Observations module allows managers, supervisors, and employees to conduct observations on employees involved in safety critical behavior. IndustrySafe’s pre-built BBS checklists may be used as is, or can be customized to better suit the needs of your organization.

  • Why Is Near Miss Reporting Important?

    A near miss is an accident that's waiting to happen. Learn how to investigate these close calls and prevent more serious incidents from occurring in the future.

  • Get the Ultimate Guide to Safety Training

    When it comes to safety training, no matter the industry, there are always questions regarding requirements and certifications. We’ve put together a guide on key safety training topics, requirements for certifications, and answers to common FAQs.

  • Industry Safe
comments powered by Disqus

OH&S Digital Edition

  • OHS Magazine Digital Edition - May 2019

    May 2019


      Why Pick a PAPR? 
      Fire Safety: Plan, Prevent, Train, Recover
      The Truth About Heat Stress and FRC
      Underestimated No More
    View This Issue